Kintor Pharmaceutical shares surged 147% on news of Covid-19 drug efficacy
Kintor Pharmaceutical shares surged 147% on news of Covid-19 drug efficacy
$KINTOR PHARMA-B(09939.HK)$ shares soared in Hong Kong trading after the company said a new drug proved effective in treating Covid-19 patients.
$金达医药-B(09939.HK)$在该公司宣布一种新药被证明对治疗新冠肺炎患者有效后，该公司股价在香港交易中飙升。
Shares of the Chinese drug developer more than doubled after initally jumping 229% closer to the open on Wednesday. The $KINTOR PHARMA-B(09939.HK)$ increased 147.5% to 34.60 as at 10.59 am.
这家中国医药开发商的股价在周三开盘时上涨了229%，涨幅超过一倍。这个$金达医药-B(09939.HK)$截至上午10时59分，增长147.5%至34.6
Kintor said before the start of trading that a clinical trial for its proxalutamide drug candidate had effectively reduced the risk of hospitalization and death in outpatients with mild-to-moderate cases of Covid-19, including patients with high-risk factors such as older age.
Kintor在开盘前表示，其候选丙沙鲁胺药物的临床试验有效地降低了新冠肺炎轻中度病例(包括年龄等高危因素患者)门诊患者的住院和死亡风险。
The drug also provided some relief to Covid-19-related symptoms such as fever, shortness of breath and coughing.
该药还对新冠肺炎相关症状有一定缓解作用，如发烧、呼吸急促和咳嗽。
It said there were no serious adverse reactions among patients in the Phase 3 study, which examined more than 700 patients mainly from the U.S.
该公司表示，在第三阶段研究中，患者没有出现严重的不良反应，该研究检查了700多名主要来自美国的患者。
Write to Ben Otto at ben.otto@wsj.com
写信给Ben Otto，电子邮件：ben.otto@wsj.com